Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4281]

NICE extends use of trastuzumab deruxtecan to earlier in the treatment of HER2 positive metastatic breast cancer

NICE extends use of trastuzumab deruxtecan to earlier in the treatment of HER2 positive metastatic breast cancer

Gene modification can reduce the risk of breast cancer

Gene modification can reduce the risk of breast cancer

Technique for tracking resistant cancer cells could lead to new treatments for relapsing breast cancer patients

Technique for tracking resistant cancer cells could lead to new treatments for relapsing breast cancer patients

Palbociclib combination in advanced breast cancer: Again only disadvantages

Palbociclib combination in advanced breast cancer: Again only disadvantages

Clues found regarding tumour suppressor gene’s breast cancer activity

Clues found regarding tumour suppressor gene’s breast cancer activity

SABCS 2022: Breast-conserving therapy may be a treatment option for some patients with multiple breast lesions

SABCS 2022: Breast-conserving therapy may be a treatment option for some patients with multiple breast lesions

SABCS 2022: Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not experience worse short-term recurrence rates

SABCS 2022: Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not experience worse...

SABCS 2022: Camizestrant may be superior to fulvestrant in hormone receptor-positive, HER2-negative breast cancer

SABCS 2022: Camizestrant may be superior to fulvestrant in hormone receptor-positive, HER2-negative breast cancer

SABCS 2022: Genetic profiling may identify patients with breast cancer who can safely omit radiation therapy after breast-conserving surgery

SABCS 2022: Genetic profiling may identify patients with breast cancer who can safely omit radiation therapy after...

SABCS 2022: The TAILORx trial in over 10,000 women with early breast cancer reaches 12 years of recurrence and survival outcomes

SABCS 2022: The TAILORx trial in over 10,000 women with early breast cancer reaches 12 years of recurrence and...

More from ecancer